|
Post by seanismorris on Aug 9, 2016 16:51:20 GMT -5
Any downgrades since the conference call are meaningless. None of these guys were on the call asking questions...
That said, MannKind remains in a difficult place with regards to financing. If anyone looks at the burn rate and how long it takes for a diabetes drug to be successful (and profitable) they are going to have a sell rating.
A new CEO doesn't change things unless he brings in new money (and yes dilution). The problem is not the plan, the problem is time running out before it can be executed.
In my opinion it took way to much time to address the Label. I'm glad they finally mentioned it, but if we are talking about months of back and forth with the FDA it's to late. We need an improved Label by the end of the year! (at the latest).
Next year the burn rate is going to skyrocket starting the TS prospect trials. The initial trials have to be done before a partner shows up. Matt knows what's coming and he's right to be nervous.
Our best bet is increased scripts and an overseas partner for Afrezza, but I don't know how we get their without an improved Label. If we are forced to accept fire sale prices (licensing Afrezza) is the company worth it market cap? Probably not.
|
|
|
Post by surplusvalue on Aug 9, 2016 17:47:20 GMT -5
Any downgrades since the conference call are meaningless. None of these guys were on the call asking questions... That said, MannKind remains in a difficult place with regards to financing. If anyone looks at the burn rate and how long it takes for a diabetes drug to be successful (and profitable) they are going to have a sell rating. A new CEO doesn't change things unless he brings in new money (and yes dilution). The problem is not the plan, the problem is time running out before it can be executed. In my opinion it took way to much time to address the Label. I'm glad they finally mentioned it, but if we are talking about months of back and forth with the FDA it's to late. We need an improved Label by the end of the year! (at the latest). Next year the burn rate is going to skyrocket starting the TS prospect trials. The initial trials have to be done before a partner shows up. Matt knows what's coming and he's right to be nervous. Our best bet is increased scripts and an overseas partner for Afrezza, but I don't know how we get their without an improved Label. If we are forced to accept fire sale prices (licensing Afrezza) is the company worth it market cap? Probably not. The limitations imposed by the FDA on Afrezza's label was perhaps the singular most important issue that prevented MNKD from any reasonable competitive success first round with Sanofi. I was ranting for over a year at YMB about why Sanofi had not even started any studies for a label change. This specific failure on Sanofi's part is the clearest indication of sabotage and malfeasance by Sanofi. MNKD handing over so much control also bears on this. More delay in acquiring a label change is highly destructive and as you say needs to be done "yesterday"
|
|
|
Post by brentie on Aug 9, 2016 18:15:26 GMT -5
|
|
|
Post by gamblerjag on Aug 9, 2016 21:30:29 GMT -5
For those that thought Matt sounded nervous on the CC.. I just don't hear it... not refusing to hear .. just don't.. Actually I thought he sounded compose. And for those that thought that he did sound nervous and that Disosto will replace him.. why would Matt need to be nervous if Disosto plan replacement is around the corner.. Makes no sense.. To me the facts are Matt sounded great and layed out the plan, Mike sounded awesome as always and don't feel he was blowing any bs.
|
|
|
Post by mannmade on Aug 9, 2016 22:25:05 GMT -5
I could be wrong but I don't see desisto coming back for a few reasons as follows: 1. They can't afford his salary 2. Matt has hired all the key players now at mnkd a new boss typically likes to work w his own senior execs 3. Matt seems to have a reasonable plan in place and desisto will not want to come in to take over someone else's plan and to change course now will be too disruptive.
|
|
|
Post by dcassidy1618a on Aug 9, 2016 22:27:57 GMT -5
Downgrade from Morgan and that **** at Piper. Anyone wager they both had questions but MNKD did not take them? Are these NEW downgrades? Downgrades SINCE the conference call? Are you suggesting they downgraded because their feelings were hurt because MNKD did not take their questions? Personally, I think analyst interest in the call was probably minimal and that the number of questions reflected how many analysts were participating. www.americanbankingnews.com/2016/08/09/mannkind-corp-mnkd-stock-rating-reaffirmed-by-jpmorgan-chase-co/Includes other analysts as well.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 9, 2016 23:40:18 GMT -5
I know it sounds ridiculous but the timing is too perfect and that prick at Piper is a wise ass. I think he reiterated a sell rating but raise the price 5 cents last call. That's a douche move. I can't remember the last time Oppenheimer was on a call and they were asking a friendly question.
|
|
|
Post by prvs on Aug 10, 2016 7:25:19 GMT -5
I could be wrong but I don't see desisto coming back for a few reasons as follows: 1. They can't afford his salary 2. Matt has hired all the key players now at mnkd a new boss typically likes to work w his own senior execs 3. Matt seems to have a reasonable plan in place and desisto will not want to come in to take over someone else's plan and to change course now will be too disruptive. I could be wrong too, but I have sometimes suspected that DeSisto left a plan behind that he intended to resume execution of as soon as he was rehired. Although if he did that and it was implemented before he came back, there's the possibility that MNKD management might tell him they don't need him anymore. Have you ever wondered how they came up with the idea of hiring Mike C. and how they knew he would be available? Up until SNY exited MNKD management looked like they had no idea what to do to fix the mess they were in. SNY exits, they hire DeSisto and Voila! They become brilliant.
|
|
|
Post by sla55 on Aug 10, 2016 17:07:20 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 11, 2016 9:47:35 GMT -5
Has anyone read these and is their anything "hidden in there" This is the one thing I have learned in investing that matters. The content in these docs mean more then anything that is said on the call.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 11, 2016 9:48:36 GMT -5
Any downgrades since the conference call are meaningless. None of these guys were on the call asking questions... That said, MannKind remains in a difficult place with regards to financing. If anyone looks at the burn rate and how long it takes for a diabetes drug to be successful (and profitable) they are going to have a sell rating. A new CEO doesn't change things unless he brings in new money (and yes dilution). The problem is not the plan, the problem is time running out before it can be executed. In my opinion it took way to much time to address the Label. I'm glad they finally mentioned it, but if we are talking about months of back and forth with the FDA it's to late. We need an improved Label by the end of the year! (at the latest). Next year the burn rate is going to skyrocket starting the TS prospect trials. The initial trials have to be done before a partner shows up. Matt knows what's coming and he's right to be nervous. Our best bet is increased scripts and an overseas partner for Afrezza, but I don't know how we get their without an improved Label. If we are forced to accept fire sale prices (licensing Afrezza) is the company worth it market cap? Probably not. I couldnt care less about an upgrade or down grade on this stock. All I am saying is that it was fishy that they both did the day of and after but didnt ask questions.
|
|